Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators

Hepatology(2020)10.1002/hep.31695Source: DataRank Database

Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators is a research paper published in Hepatology (2020). On theSindex it has a DataRank of 0. It has been cited 99 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access99 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.30)OA: hybridTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Emily J. Colbeck ORCID,Stéphane Daffis,Shahzada Khan ORCID,Dhivya Ramakrishnan,Divya Pattabiraman

Live enrichment

PubMed:33368377 PMC:PMC8436741 OpenAlex:https://openalex.org/W3116103979

Wellcome Trust

Grant: 101849/Z/13/Z

Cancer Research UK

Grant: 26603

Wellcome Trust

Grant: 214191/Z/18/Z

National Institute for Health Research (NIHR)

Grant: NIHR200249

Gilead Sciences

FWCI

4.30

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.31695

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.31695

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31695

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/hep.31695

publisherhttps://journals.lww.com/10.1002/hep.31695

Fields of Study

Immune cells in cancerImmune Cell Function and InteractionHepatitis B Virus StudiesAdultAgedAnimalsAntiviral AgentsCD8-Positive T-LymphocytesCohort StudiesDisease Models, AnimalFemaleHealthy VolunteersHep G2 CellsHepatitis B, ChronicHexanolsHost-Pathogen InteractionsHumansKiller Cells, NaturalLeukocytes, MononuclearMaleMarmotaMiddle AgedPrimary Cell CulturePyrimidinesT-Lymphocytes, RegulatoryToll-Like Receptor 8Young Adult

MeSH Terms

AdultAgedHexanolsAnimalsAntiviral AgentsDisease Models, AnimalFemaleHumansKiller Cells, NaturalLeukocytes, MononuclearMaleMarmotaMiddle AgedPyrimidinesCohort StudiesCD8-Positive T-LymphocytesHepatitis B, ChronicT-Lymphocytes, RegulatoryToll-Like Receptor 8Host-Pathogen InteractionsYoung AdultHep G2 CellsPrimary Cell CultureHealthy Volunteers

Keywords

ImmunologyImmune systemBiologyCytokineCD8Interferon

Sustainable Development Goals

SDG 0: Good health and well-being

Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators

FAIR Checklist

Authors (18)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)